Matthew T. Haren

Matthew T. Haren

Auto-generated profile, based on publicly available information

Matthew T. Haren

Department of Management, Faculty of Administrative Sciences, Laval University, 2325 rue de la Terrasse, Québec, QC, G1V 0A6, Canada, 1 418 656-2131 ext 417857

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2003 in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
Verified
Journal Article
Open access
PDF file
GWGary A. Wittert
Gary A. Wittert
ICIan M. Chapman
Ian M. Chapman
MHMatthew T. Haren
Matthew T. Haren
SMShylie Mackintosh
Shylie Mackintosh
PCPenelope Coates
Penelope Coates
JMJohn E. Morley
John E. Morley
Background. Loss of muscle mass (sarcopenia) leads to frailty in older men. The decline in testosterone over the life span may contribute to this muscle loss. We studied the ability of oral testosterone to prevent muscle loss in older men over a 12-month period. Methods. A standard dose (80 mg twice daily) of testosterone undecanoate or placebo was administered for 1 year to 76 healthy men aged 60 years or older. All men had a free testosterone index of 0.3–0.5, which represents a value below the normal lower limit for young men (19–30 years), but remains within the overall normal male range. Measurements of body composition, muscle strength, hormones, and safety parameters were obtained at 0, 6, and 12 months. Results. Lean body mass increased (p =.0001) and fat mass decreased (p =.02) in the testosterone as compared with the placebo-treated group. There were no significant effects on muscle strength. There was a significant increase in hematocrit (0.02%) in the testosterone-treated group (p =.03). Plasma triglycerides, total cholesterol, and low-density lipoprotein cholesterol levels were similar in both groups, but there was a decrease in high-density lipoprotein cholesterol (−0.1 mmol/L) at 12 months in the testosterone group as compared to the placebo group (p = 0.026). There were no differences in prostate-specific antigen or systolic or diastolic blood pressure between the groups. Conclusion. Oral testosterone administration to older relatively hypogonadal men results in an increase in muscle mass and a decrease in body fat.

1 July 2009 in Metabolism
Verified
Journal Article
Closed access
EAEvan Atlantis
Evan Atlantis
SMSean A. Martin
Sean A. Martin
MHMatthew T. Haren
Matthew T. Haren
ATAnne Taylor
Anne Taylor
GWGary A. Wittert
Gary A. Wittert


21 October 2010 in World Journal of Urology
Verified
Journal Article
Closed access
PDF file
MSMembers of the Florey Adelaide Male Ageing Study
Members of the Florey Adelaide Male Ageing Study
SMSean A. Martin
Sean A. Martin
MHMatthew T. Haren
Matthew T. Haren
VMVillis R. Marshall
Villis R. Marshall
KLKylie Lange
Kylie Lange
GWGary A. Wittert
Gary A. Wittert

1 September 2006 in Medical Clinics of North America
Verified
Journal Article
Closed access
JMJohn E. Morley
John E. Morley
MHMatthew T. Haren
Matthew T. Haren
YRYves Rolland
Yves Rolland
MKMoon Jong Kim
Moon Jong Kim

3 October 2006 in International Journal of Andrology
Verified
Journal Article
Open access
PDF file
RARavinder Anand-Ivell
Ravinder Anand-Ivell
JWJessica Wohlgemuth
Jessica Wohlgemuth
MHMatthew T. Haren
Matthew T. Haren
PHPerdita J. Hope
Perdita J. Hope
GHGeorge Hatzinikolas
George Hatzinikolas
RIRichard Ivell
Richard Ivell
Summary: The novel peptide hormone insulin‐like peptide 3 (INSL3) is a major secretory product of the Leydig cells of the testis, and in adult men is secreted into the blood, giving rise to circulating concentrations ranging from 0.5 to 2.5 ng/mL. We studied a large randomly recruited cohort of 1183 men from South Australia, comparing serum INSL3 concentrations with age, and a variety of endocrine, cognitive and morphological parameters. While INSL3 concentration declines significantly (p < 0.001) and continuously with age from 1.29 ± 0.47 ng/mL in young men (age 35–44 years) to 0.79 ± 0.39 ng/mL in the age group 75–80 years, there is no correlation with testosterone or components of the hypothalamo‐pituitary‐gonadal (HPG) axis, independent of age, nor with any other parameter measured, including thyroid or prostate status and obesity. For men exhibiting normal follicle stimulating hormone (FSH) and high luteinizing hormone (LH) levels, there was a significant inverse correlation with plasma oestradiol. Unilaterally orchidectomized men had INSL3 values intermediate between intact men and anorchid subjects, and showed inverse correlations (p < 0.001) between INSL3 and FSH or LH concentrations, which were independent of age. Taken together, the data show that INSL3 is an independent measure of Leydig cell function (quality and number), which appears to be independent of acute control via the HPG axis. Its decline with age reflects a decline in the properties of the Leydig cell population only, and emphasizes a gonadal component in the age‐related decrease in androgen production.